The production of monoclonal antibodes reactive with human tumour-associated antigens has led to interest in their use for selective delivery of therapeutic agents to tumour sites The single binding site of each bispecific antibody specific for the toxic moiety makes the approach initially most attractive for toxins, where internalisation of only a few molecules may be needed to produce cytotoxic effects. Such constructs have been used to target ricin A chain (Webb et al., 1985) and saporin (Glennie et al., 1988) . However, Corvalan et al. (1987a, b) have used the bispecific approach with a conventional drug, showing that a hybrid antibody to CEA and vinca alkaloid altered the biodistribution of the drug, and increased its uptake into tumour xenografts. Treatment with antibody and drug showed synergistic therapeutic effects, although anti-tumour effects of the antibody itself may have contributed significantly to the overall response.
More effective application of bispecific antibodies to conventional drug targeting could be via a carrier to which multiple drug molecules are linked. In addition to delivering more drug per antibody molecule, this approach has the advantage that the toxic and targeting moieties could be given separately, with better tissue penetration of the smaller component parts, and the possibility of pre-localisation of the targeting moiety.
The anti-conjugate specificity of the bispecific antibody could be for the carrier or the drug. An anti-carrier bispecific antibody could be used with a range of drugs linked to the same carrier, but for clinical use, this carrier obviously could not be a human protein. A carrier for this purpose would nevertheless require to be poorly immunogenic in humans, but sufficiently immunogenic in other species to allow production of a monoclonal antibody. Alternatively, an antidrug specificity could be used, selecting an antibody that binds to carrier conjugated drug, allowing the use of a human protein or a non-immunogenic polymer as carrier. In this case, the binding activity of the antibody to free drug should not be high in comparison to conjugated drug, to ensure that free drug released during conjugate metabolism does not displace conjugate from the targeting moiety.
The last approach has been evaluated in the present study. A hybrid hybridoma producing bispecific monoclonal antibody reactive with a gp72 human tumour associated cell surface antigen and with methotrexate (MTX) preferentially in the form of methotrexate-human serum albumin conjugate (MTX-HSA) has been produced. A technique for isolating the bispecific antibody from the hybridoma culture supernatant, using an immunoabsorbent of MTX in conjunction with protein A, has been developed. The ability of the purified bispecific antibody to bridge between cell surface tumour antigen and MTX-HSA and its effect on the cytotoxicity of this conjugate has been assessed.
Materials and methods
Tumour cell lines Lines of the gp72 positive human osteosarcomas 791T and 788T, bladder carcinoma T24 and colon carcinoma C 170 which express only low levels of gp72, and gp72 negative colon carcinoma Colo-205 were maintained in tissue culture in Dulbecco's MEM with 10% fetal calf serum or MEM with 10% newborn calf serum. They were harvested with trypsin-EDTA for use in in vitro assays.
Methotrexate and conjugates L-Methotrexate (MTX) was obtained from Lederle (Gosport, Hampshire, UK). MTX conjugated to human serum albumin (HSA) at molar ratios of 23:1-40:1, prepared by carbodiimide coupling of MTX to HSA (Garnett et al., 1983) , was supplied by Dr M.C. Garnett of this department. MTXthyroglobulin conjugate prepared by a similar procedure was a gift from Dr G.W. Aherne (Department of Biochemistry, University of Surrey, UK). resistant 791T/36/3 hybridoma cells (Embleton et al., 1981) and the products were plated in two 96-well Stepwise elution with pH 6.0 and then pH 3.0, 0.1 M citrate buffer or 3 M sodium thiocyanate was then carried out, and the eluted fractions dialysed against PBS. The pH 6 eluate (putatively anti-MTX antibody) contained only IgGI (mean yield 16 jig ml-'), and the pH 3 or sodium thiocyanate eluates (putatively hybrid antibody) contained both isotypes (mean yield 8 jig ml-'). Method B This was designed to isolate anti-gp72 antibody as well as the bispecific and anti-MTX components. Hybridoma culture supernatant was applied first to the Protein A column, and elution carried out at pH 6.0 (mean yield 17 jig ml-' of putative anti-MTX antibody) and at pH 3 (to give a mixture of hybrid and anti-gp72 antibodies). After dialysis against PBS, protein eluted in the second peak was applied to the MTX-agarose column giving an unbound fraction (mean yield 37 jig ml-' of putative anti-gp72 antibody) and bound material which was subsequently eluted with pH 3.0 buffer (mean yield 6 jg ml-' of putative hybrid antibody). To demonstrate the ability of purified antibody preparations to react simultaneously with gp72 tumour cell surface antigen and with MTX-HSA, tumour cells were suspended in 0.5 ml of medium containing 5 jLg of antibody and 4 jig of MTX-HSA conjugate. Subsequently the cells were treated with 1/40 dilution of FITC labelled rabbit-anti-HSA anti-HSA antiserum (Dako Ltd) . Negative controls here included cells treated with monoclonal antibodies alone followed by FITC-anti-HSA. The fluorescence of the cells was quantified under standardized conditions of analysis (Roe et al., 1985) . Briefly, 200 mW of 488 nm light from an argon laser was used to excite fluorescence, which was collected via a 10 nm bandwidth bandpass filter centred at 515 nm. Mean channel number was determined for distributions containing 2,000-5,000 cells, and taking into account the amplification used, a mean linear fluorescence value was calculated. 
Cytotoxicity assays

Specificity of MTX binding of bispecific antibody
The specificity of MTX binding of bispecific antibody was examined in competitive ELISA assays. In the first test (Table IV) in which hybrid antibody was at 100 pg ml-', the addition of 1 g ml-' of MTX as MTX-HSA reduced the final optical density of the ELISA reaction by 88%, with almost complete inhibition at higher concentrations. In contrast free MTX even at 10 tg ml-' only reduced the final optical density by 54%, and to achieve inhibition similar to that seen with I jg ml-' of MTX as MTX-HSA the concentration of free drug had to be increased to 100 jig ml- ' Osteogenic sarcoma 791T and bladder carcinoma T24 cells were treated in vitro with the bispecific antibody fraction at a constant concentration of 3 jLg ml-', and free MTX, titrated from 100 ng ml-' to 1 ng ml-'. As expected from the binding characteristics of the anti-methotrexate moiety, the bispecific antibody did not affect the cytotoxicity of free MTX: 50% inhibitory concentrations (IC50) of 3.5 and 3.7 ng ml-' MTX were observed for 791 T in the presence and absence of antibody, respectively, and 1.9 and 1.7 ng ml-' in the case of T24.
An initial experiment was then performed with MTX-HSA in which the bispecific antibody was again used at 3 jig ml-' (Figure 1) . The MTX-HSA conjugate alone was slightly more active against T24 than 791T, reflecting the greater sensitivity of T24 to the free drug. In the case of T24 cytotoxicity was virtually the same whether or not antibody was present, but the antibody signficantly enhanced the effect against 791T cells at concentrations of conjugate below 3 jLg ml-' in terms of MTX content. The lack of augmentation at higher conjugate concentrations suggested that the system might be in antigen excess, so further tests on 791T were conducted with MTX-HSA at a low (non-toxic) dose of 0.25 jig ml-', and antibody was titrated downwards from 50 jig ml-' (Figure 2) . The cytotoxicity of MTX-HSA was markedly increased by addition of bispecific antibody, the response correlating with antibody concentration. In contrast, the monospecific anti-MTX antibody fraction and parental 791T/36 (anti-gp72) did not induce augmentation of cytotoxicity by MTX-HSA, and addition of bispecific antibody alone (i.e. without the conjugate) did not affect target cell survival.
In order to evaluate the specificity of the effect of the bispecific antibody, experiments were also carried out with osteogenic sarcoma 788T, which, like 791T, expresses a high -ZU I cell), and tumour lines T24 and C1 70 which express onl about 5-10% of this gp72 level. These lines were chose because they have similar growth rates to 791T, and simila sensitivity to MTX. The results (Figure 3) show that 788' was highly susceptible to the combined action of MTX-HS1 and bispecific antibody, but T24 and C170 were unaffected a the concentrations tested. In this experiment MTX-HSA (0.25 yg ml-') in the absence of antibody produced cytotoy icities of 3% against 788T and below zero against T24 an C170. The selective effect of bispecific antibody against 791 and 788T confirms that binding of the anti-gp72 moiety wa necessary for the mediation of cytotoxicity.
A comparison between free MTX and MTX-HSA wa carried out using the 788T cell line and bispecific antibody a a constant concentration of 10 agml-', which was highl effective with this cell line (Figure 3) . As shown in Figure a the antibody produced no change in the titration of fre drug, but again enhanced the effect of MTX-HSA at lo' conjugate concentrations, although there was no difference a the highest concentrations used. This synergism with th conjugate but not free MTX at the lower equitoxic dose correlates with greater binding affinity of the bispecifi antibody for conjugated drug, and the availability of mor MTX residues per mole of conjugate compared with the fre drug (i.e. target cell binding of one residue of MTX in th conjugate can result in internalisation of many others on th same molecule).
Discussion
The aim of the present study was to generate a hybri hybridoma producing bispecific monoclonal antibody reac tive with gp72 human tumour associated antigen and MT) in the form of a MTX-HSA conjugate, to isolate th antibody from hybridoma culture supernatant and t examine its effect on the cytotoxicity of MTX-HSA.
Bispecific antibodies can be made by chemical conjugatior the use of heterobifunctional reagents allows production c bispecific antibodies in high yield (Glennie et al., 1988 although preparation of appropriate antibody fragments ma be a problem, as with the IgG2b 791T/36 in the curren study. Alternatively, fusion of two hybridomas or a hybrid oma with immune spleen cells can be undertaken, with ap propriate physical (Karawajew et al., 1987) or biochemica selection of hybrid hybridomas (Webb et al., 1985; Corvala & Smith, 1987) . Once established, hybrid hybridomas ca produce a continual supply of antibody, although th ie theoretical maximum yield of bispecific antibody will be 50% ne of the total immunoglobulin synthesised, the remainder in this case being bivalent parent antibodies. It should be appreciated that much lower proportions of bispecific antibody can be produced as a result of other heavy:light chain reassociations (Milstein & Cuello, 1984) . These considerations id means that it will always be necessary when using the hybrid- The definitive demonstration that fractions from the al purification procedures contained bispecific antibody and not In simply a mixture of two co-purified antibodies came from the In flow cytometry assays designed to detect bridging between e cell surface bound antibody and MTX in the form of MTX-HSA (Table III) . The fractions containing both isotypes and reactive with both antigens when tested separately, could react simultaneously with gp72 antigen on 791T cells and with MTX-HSA.
It was proposed that the bispecific antibody produced should have highest affinity for MTX conjugated to HSA. Mice were originally immunised with such a conjugate and initial screening for antibody was carried out against MTX-HSA in the continued presence of the free MTX in HMT medium to encourage selection of those antibodies with preferential binding to the conjugate. The binding of purified hybrid antibody to immobilised MTX-HSA was inhibited by soluble MTX-HSA, but not by HSA, and was poorly inhibited by an equivalent amount of free MTX (Table IV) . MTX-thyroglobulin also inhibited binding of the bispecific antibody but only about 50% as efficiently as MTX as MTX-HSA. Overall the interpretation is that this bispecific antibody reacts with highest affinity against MTX conjugated 0 to HSA, although it is reacting with the MTX moiety and not with the HSA moiety.
The higher affinity of the bispecific antibody for conjugated MTX compared to free MTX is reflected in the augmentation of cytotoxicity by MTX-HSA but not the free drug in vitro (Figure 4 ). An Using osteogenic sarcoma 788T as the target cell line, 70% cytotoxicity was achieved using an antibody concentration of 1.6 Lg ml' and MTX-HSA at a concentration equivalent to 0.25 tig ml-' MTX (Figure 3) , representing a molar ratio (MTX: Ig) of about 50:1. Previous studies have shown that conjugates of anti-gp72 antibody coupled directly to MTX-HSA by a carbodiimide reaction give similar activity against this cell line at molar ratios around 30:1 (Garnett et al., 1983) . Thus, the bispecific antibody was almost as efficient as a targeting vector as the chemically linked monospecific parental antibody. However, saturation of osteosarcoma 791T cells was apparently not reached by bispecific antibody even at concentrations up to 50 jig ml-' (Figure 2 ), indicating low affinity or immunoreactivity of the purified fraction. If this could be improved, the targeting efficiency might equal or exceed that of chemically coupled anti-gp72 antibody.
Other studies using bispecific antibodies recognising plant toxins have also shown cytotoxic activities similar to those obtained with conventional immunotoxin conjugate. Thus, Webb et al. (1985) produced a hybridoma with anti-ricin toxin A chain (RTA) and anti-prostate carcinoma activity, and showed that it could mediate selective cytotoxicity against prostate tumour cells using RTA at l0-9 M together with NH4CI as a potentiator. Glennie et al. (1988) showed that chemically reconstituted bispecific antibodies recognising an immunoglobulin idiotype on guinea pig leukaemia cells and the toxin saporin could increase the toxic effect of saporin for leukaemia cells by almost 5 log units compared to the toxin alone.
Further studies with this bispecific antibody will examine in vivo its ability to localise in gp72 positive human tumour xenografts, to alter the biodistribution of MTX-HSA and to bring about selective targeting of this conjugate to tumours. Earlier studies with covalent conjugates of 791T/36 antibody and MTX have shown blood survival and site specific localisation of both antibody and drug moieties of the conjugates in xenografts and blood survival of both moieties and tumour localisation of at least antibody in primary colo-rectal carcinoma (Ballantyne et al., 1988) . However, the maximum molar ratio of MTX to antibody feasible with those conjugates, at about 3:1, is viewed as a limitation to their therapeutic efficacy . It has been shown in the present studies that bispecific antibody can react with MTX-HSA conjugates with up to 40 MTX molecules per HSA molecule. It is therefore feasible that each bispecific antibody molecule deposited in tumour tissue could, in capturing one such molecule via only one of its MTX groups, encourage selective localisation of many more drug molecules than is possible with direct covalent conjugation of the drug to 791T/36 monoclonal antibody.
